Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-08-22 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于减少注册资本通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the reduction of registered capital due to the repurchase and cancellation of restricted stock under an incentive plan. It notifies creditors about the capital reduction and provides instructions for debt claims within a specified period. The document includes legal references and procedural details but does not contain financial statements or detailed financial analysis. It is a formal notice to creditors about a capital change, which aligns with announcements related to capital structure changes but is not a full financial report or detailed capital update. Given the nature of the announcement about capital reduction and creditor notification, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is short and focused on the capital change announcement, not a full report or regulatory filing. Confidence is high due to clear content and context.
2023-08-22 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on the company's 2023 semi-annual report and the use of raised funds for the first half of 2023. It references the 2023 half-year report and related regulatory compliance but does not contain the actual financial statements or detailed financial data itself. The document is a formal announcement of the independent directors' review and approval of these matters, consistent with regulatory requirements. The document length is short (1089 characters), and it serves as an announcement or opinion related to the semi-annual report rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related announcement and opinion rather than the full interim report (IR).
2023-08-22 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business overview, shareholder structure, and other substantive financial and operational information. The length of the document (6865 characters) and the presence of actual financial data and analysis confirm it is a financial report rather than a mere announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
2023年半年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (332 characters) from Jiangsu Deyuan Pharmaceutical Co., Ltd. It states that the company's 2023 semi-annual report and summary were disclosed on August 23, 2023, on the official information disclosure platform. The text does not contain the actual semi-annual report or substantive financial data but rather directs investors to where the report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the report itself (IR).
2023-08-22 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder meeting decisions and voting outcomes rather than presenting a full report or financial statements. The document length is short (1553 characters), and it is clearly a resolution announcement from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-08-22 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2023 to June 30, 2023. It contains detailed financial data including income, profit, assets, liabilities, and cash flow, as well as management discussion on business operations, risks, and industry environment. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes sections such as "会计数据和经营情况" (Accounting Data and Operating Conditions), "财务会计报告" (Financial Accounting Report), and detailed financial tables. The document explicitly states it is a half-year report and contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.